Karl Thor, PhD

I received my PhD from U. of Pittsburgh Medical School in Pharmacology in 1985, where I was funded by PHARMA predoctoral fellowship. Postdoctoral fellow at Uniformed Services University, Bethesda, MD, Dept. Pharmacology (1985-88) and Adj. Asst. Prof. (1988-89). Senior Staff Fellow at NIH in Lab of Neurophysiology (1989-90). Senior scientist at Eli Lilly and company, where I discovered the first internationally approved and marketed product for stress urinary incontinence (1990-98). I also served as an Adj. Assoc. Prof. in the Depts. of Pharmacology and Urology at Indiana U. I then founded PPD GenuPro (1998-2002) where I discovered the first internationally approved and marketed product for premature ejaculation. From 1997-2010 I also held an appointment as Res. Assoc. Prof at Duke U. Med Center and Director of the Lab of NeuroUrology in the Durham VA. In 2006 I founded Urogenix, which was immediately acquired by Astellas Pharmaceuticals, where I placed 1 compounds into clinical development for stress incontinence. In 2012 Astellas pulled all research from the US back into Japan, at which point I founded Dignify Therapeutics, which now has 3 products imminent for clinical development. I have served on various FDA Guidance panels, NIH study sections, and editorial boards.